 Manufacture of pharmaceutical dosage forms |
| OF THE INVENTION The present invention is directed to solid, unit dosage forms primarily for oral ... |
|
| Device comprising liner for protecting fluid sensitive medicament |
| OF THE DRAWING FIGURES Turning now to the drawings in detail, which are examples of various ... |
|
| In situ active compound assembly |
| I claim: 1. A method to modify a target condition contained within an environment with a conjugate ... |
|
| Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein |
| The invention is directed to a method for the prophylaxis or treatment of an animal for systemic ... |
|
| Anti-bronchoconstriction 2-(4'-pyridinyl)-thiazole derivatives, composition, and method of use therefor |
| We claim: 1. A compound having the structural formula I ##STR4## wherein R is cyano, ##STR5## --C(.... |
|
| Antioxidant-induced apoptosis in vascular smooth muscle cells |
| The invention is based on the discovery that, unlike other cell types, vascular smooth muscle cells ... |
|
| Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors |
| In a method aspect, this invention relates to a method of treating the climacterium symptoms in a ... |
|
|
Specifically .beta.-.beta. cross-linked hemoglobins and method of preparation
| Details |
Inventors: Kluger, Ronald; Wodzinska, Jolanta;
Assignee: The University of Toronto Innovations Foundation (Toronto, CA)
Primary Examiner: Wityshyn; Michael G.
Assistant Examiner: Touzeau; P. Lynn
Attorney, Agent or Firm: Bereskin & Parr
A modified hemoglobin comprising hemoglobin which is cross-linked with a cross-linking reagent. The cross-linking reagent is selected such that the .beta.-chains are cross-linked within the 2,3-diphosphoglycerate binding site and the linkage distance between the .beta.-chains is between about 5 to 9 angstroms. A method of preparing the modified hemoglobin and its use as a blood substitute or a plasma expander are also described. |
|
DETAILED DESCRIPTION The present invention provides a modified hemoglobin comprising hemoglobin which is cross-linked with a cross-linking reagent, said cross-linking reagent being selected such that the .
beta.
-chains are cross-linked within the 2,3-diphosphoglycerate binding site and the distance between the .
beta.
-chains is between about 5 to 9 angstroms.
Preferably, the cross-linking reagent is selected such that the .
beta.
-chains are cross-linked between the epsilon amino group of lysine-82 of one chain and the alpha amino group of valine-1 of the other chain and the distance between the .
beta.
-chains is about 7 angstroms.
In accordance with one embodiment of the invention a modified hemoglobin is provided which is obtained by cross-linking hemoglobin with a cross-linking reagent comprising an aromatic- or aliphatic-derived acyl material having at least two anionic leaving groups each anionic leaving group being adjacent to an electrophile group, said cross-linking reagent being selected such that a first electrophile group reacts covalently with the epsilon group lysine 82 of a first .
beta.
chain of said hemoglobin and a second electrophile group reacts covalently with the alpha amino group valine-1 of a second .
beta.
chain of said modified hemoglobin whereby said hemoglobin is intramolecularly cross-linked between said beta chains such that the distance between the .
beta.
chains at said cross-link is between about 5 to 9 angstroms.
Preferably, the cross-linking reagent comprises an aromatic- or aliphatic-derived acyl material having at least three anionic leaving groups and wherein a third electrophile group reacts covalently with the epsilon group lysine 82 of said second .
beta.
chain of said hemoglobin or the alpha amino group valine-1 of said first .
beta.
chain of said hemoglobin.
The cross-linking reagent may comprise an aromatic- or aliphatic-derived acyl material having at least four anionic leaving groups and a fourth electrophile group may react covalently with the alpha amino group valine-1 of said first
|
| Related patents |
|
|
Apparatus for manufacturing granulated material
The invention proceeds from the consideration that it is not possible to reduce the width of the slit, especially at high production rates i.e., at high relative ...
|
|
|
Substituted and bridged pyridines useful as calcium channel blockers
OF THE INVENTION The specific substituted and bridged pyridine compounds of this invention are represented by the following general structural formula (I): ##STR1## ...
|
|
|
Ace inhibitors in macular degeneration
OF THE INVENTION The novel method of treatment of senile macular degeneration of this invention comprises the administration to a patient in need of such treatment of ...
|
|
|
Derivatives of 2,3,4,5,6,7-hexahydro-2,7-methano-1,5-benzoxazonines and -1,4-benzoxazonines, processes for their production and their use as pharmaceuticals
We claim: 1. 2,3,4,5,6,7-Hexahydro-2,7-methano-1,5-benzoxazonine and -1,4-benzoxazonine compounds, of the formula ##STR15## wherein: R.sub.1 is hydrogen or C.sub.1 -C....
|
|
|
Novel benzylalcohol derivatives and processes for preparing the same
What we claim is: 1. A compound of the formula: ##STR11## wherein R is a lower alkyl group having 1-4 carbon atoms, or a pharmaceutically acceptable acid addition salt ...
|
|
|
Method of use of bicycloheptane substituted prostaglandin analogs as cardiovascular agents
What is claimed is: 1. A method of inhibiting arachidonic acid-induced platelet aggregation and bronchoconstriction, which comprises administering to the circulatory ...
|
|
|
1-arylsulphonyl-2-piperidinone derivatives, process and intermediates for the preparation thereof, their application as antispasmodics and compositions containing them
What is claimed is: 1. The compound of formula (I): ##STR11## in which R represents the radical ##STR12## in which R.sub.1 at any position on the benzene ring represents ...
|
|
|
Dihydropyridine derivatives and pharmaceutical composition thereof
OF THE INVENTION This invention relates to dihydropyridine derivatives represented by the formula (I) ##STR2## wherein R.sub.1, R.sub.2 and R.sub.3 are the same or ...
|
|
|
1-[2-(1H-inden-3-yl)ethyl]-4-(naphth-1-yl)piperazine derivatives, their preparation and their application in therapeutics
We claim: 1. A compound of the formula: ##STR6## in which X represents a hydrogen atom, a C.sub.1 -C.sub.3 alkoxy group or a cyclopropylmethoxy group, and Y represents a ...
|
|
|
Use of fedotozine in the treatment of functional states of intestinal obstructions
We claim: 1. Process for inhibiting functional ileus in a patient, which consists of administering a therapeutically effective dose of (+)-1-[(3,4,5-trimethoxy)...
|
|
|
Vasodialators 
